Nos2 Nitric Oxide Synthase 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Overview |
|---|
| Gene Symbol | NOS2 |
| Full Name | Nitric Oxide Synthase 2 |
| Chromosomal Location | 17q11.2 |
| Protein Product | Inducible Nitric Oxide Synthase (iNOS) |
| Molecular Weight | ~131 kDa |
| Gene Family | Nitric oxide synthase family |
The NOS2 gene encodes inducible nitric oxide synthase (iNOS), a key enzyme responsible for producing nitric oxide (NO) in response to inflammatory stimuli. Unlike the other NOS isoforms (nNOS and eNOS), iNOS is not constitutively expressed but is induced by cytokines, bacterial lipopolysaccharides (LPS), and other inflammatory signals. Once induced, iNOS can produce large amounts of NO for extended periods, making it a critical mediator of the immune response and inflammatory diseases.
The NOS2 gene spans approximately 37 kb and consists of 26 exons. The promoter region contains multiple transcription factor binding sites, including NF-κB, STAT-1, AP-1, and CREB, which mediate its induction by inflammatory stimuli. Several polymorphisms in the NOS2 promoter have been associated with altered susceptibility to inflammatory and neurodegenerative diseases.
iNOS is a homodimeric enzyme, with each monomer containing:
- N-terminal oxygenase domain: Binds heme (Fe-protoporphyrin IX), tetrahydrobiopterin (BH4), and L-arginine
- C-terminal reductase domain: Contains FMN, FAD, and NADPH binding sites
- Calmodulin-binding domain: iNOS is constitutively bound to calmodulin, unlike nNOS and eNOS which require calcium/calmodulin for activation
The dimerization of iNOS is essential for catalytic activity, as the oxygenase domains from each monomer form a functional active site.
In the immune system, iNOS-mediated NO production serves several critical functions:
- Antimicrobial defense: NO and its reactive nitrogen intermediates (RNI) kill bacteria, viruses, fungi, and parasites
- Immune regulation: NO modulates T-cell function, macrophage activation, and cytokine production
- Vasodilation: NO produced by immune cells contributes to increased blood flow during inflammation
- Signal transduction: NO acts as a signaling molecule, affecting gene expression through s-nitrosylation
In the brain, iNOS is expressed in astrocytes, microglia, and neurons in response to injury or disease.
iNOS expression is highly inducible in:
- Macrophages and microglia: Primary immune cells expressing iNOS
- Astrocytes: Reactive astrocytes in injured brain
- Neurons: Certain neuronal populations under pathological conditions
- Endothelial cells: During inflammatory responses
- ** hepatocytes**: In response to cytokines
Expression is controlled at multiple levels: transcriptional induction, mRNA stability, and protein stability.
- iNOS is upregulated in AD brain, particularly around amyloid plaques
- Excessive NO production contributes to oxidative stress and nitrative damage
- NO interacts with Aβ to form toxic species
- iNOS deficiency reduces amyloid pathology in mouse models
- Therapeutic targeting: iNOS inhibitors in development
- Increased iNOS expression in substantia nigra of PD patients
- NO contributes to dopaminergic neuron death through:
- Mitochondrial dysfunction
- Protein nitration
- DNA damage
- Inflammation-induced iNOS exacerbates MPTP toxicity
- iNOS knockout mice show protected dopaminergic neurons
- iNOS elevated in ALS spinal cord and motor cortex
- NO contributes to motor neuron injury through oxidative damage
- Astrocytic iNOS may propagate neuroinflammation
- Correlation with disease progression
- iNOS critical for demyelination and axonal injury
- NO produced by activated microglia damages oligodendrocytes
- iNOS inhibition reduces disease severity in EAE model
- Therapeutic potential of iNOS modulators
¶ Stroke and Brain Injury
- iNOS induced after ischemic injury
- NO contributes to excitotoxic damage
- Timing-dependent effects (early vs. late iNOS)
- iNOS deletion reduces infarct size
| Approach |
Status |
Notes |
| iNOS inhibitors |
Preclinical |
L-NIL, 1400W showing promise |
| NOS isoform-selective |
Research |
Avoiding eNOS/nNOS inhibition |
| BH4 supplementation |
Research |
Co-factor availability |
| Antioxidants |
Clinical |
Indirectly reduce NO toxicity |
| Anti-inflammatory |
Clinical |
Reduce iNOS induction |
- NOS2 knockout mice: Used to study iNOS function in disease models
- iNOS transgenic mice: Overexpression models for neuroinflammation
- Conditioned iNOS mice: Inducible expression systems
- ** isoform-selective inhibitors**: Developing drugs that specifically target iNOS without affecting nNOS/eNOS
- Blood-brain barrier penetration: Improving delivery of iNOS inhibitors to CNS
- Timing of intervention: Understanding the temporal role of NO in disease progression
- Biomarker development: NO metabolites as disease markers
- Gene therapy: Targeted delivery of iNOS modulators
The study of Nos2 Nitric Oxide Synthase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78(6):915-918. PMID:8087342
- Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75(6):639-653. PMID:15158681
- Stewart VC, et al. iNOS expression in brain. Neurochem Int. 2000;37(2-3):223-228. PMID:10964188
- Huang Z, et al. Effects of iNOS deficiency in models of neurodegeneration. J Neurochem. 2020;155(3):289-304. PMID:32380523
- Xie QW, et al. Cloning and characterization of iNOS. Science. 1992;256(5054):225-228. PMID:1373522
- Guix FX, et al. NO in Alzheimer's disease. Antioxid Redox Signal. 2021;35(8):618-637. PMID:33491327
- Liu B, et al. iNOS in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121:110879. PMID:36921628
- Saha RN, et al. iNOS in neuroinflammation. Neurochem Int. 2019;130:104314. PMID:30639743